Loading organizations...
§ Private Profile · Houston, TX, USA
Clinical-stage biotechnology company developing novel targeted cancer therapeutics for oncology, focused on desmoid tumors and.
Iterion Therapeutics is a clinical-stage biotechnology company based in Houston, TX, United States, focused on developing novel targeted cancer therapeutics. Its lead asset, tegavivint, is an investigational small molecule designed to inhibit TBL1, thereby blocking nuclear beta-catenin signaling and oncogenic activity in multiple cancer types. The company specifically targets indications such as desmoid tumors, where 80-90% of patients exhibit beta-catenin mutations, and has presented Phase 1 study data for tegavivint in this area. Key leadership includes CEO Rahul Aras, COO Jean Chang, CSO Steve Horrigan, and CMO Ovid Trifan. Formerly known as Beta Cat, Iterion Therapeutics was established in 2010; founder names are not publicly disclosed. Its business model centers on private biotech funded through venture or private investment, specific revenue or funding details unknown.
Iterion Therapeutics has raised $17.0M across 1 funding round.
Iterion Therapeutics has raised $17.0M in total across 1 funding round.
Iterion Therapeutics has raised $17.0M across 1 funding round. Most recently, it raised $17.0M Series B in February 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 16, 2021 | $17M Series B | Benjamin Rovinski, Ph.d. | Green Park & Golf Ventures, Sante Ventures, Venture Investors | Announced |
Iterion Therapeutics has raised $17.0M in total across 1 funding round.
Iterion Therapeutics's investors include Benjamin Rovinski, Ph.D., Green Park & Golf Ventures, Sante Ventures, Venture Investors.